ACP
CHRS icon

Acuta Capital Partners’s Coherus Oncology CHRS Stock Holding History

Acuta Capital Partners’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-353,500
Closed -$5.83M – 27
2018
Q3 		$5.83M Buy
353,500
+8,500
+2% +$151K 2.08% 15
2018
Q2 		$4.83M Buy
+345,000
New +$4.94M 0.86% 25

Other funds holding CHRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acuta Capital Partners's CHRS Position: Q4 2018 in Review

Acuta Capital Partners sold out of Coherus Oncology (CHRS) in Q4 2018, closing a stake of 353,500 shares — an estimated $5.83M sold.

Acuta Capital Partners first reported a position in CHRS in Q2 2018 and held it in 2 quarters. The position peaked at $5.83M in Q3 2018. 111 funds tracked by Wall St. Rank hold CHRS as of Q4 2018.

  • Acuta Capital Partners reported no remaining Coherus Oncology position as of Q4 2018 after selling out during the quarter.
  • Acuta Capital Partners sold 353,500 Coherus Oncology shares in Q4 2018, an estimated $5.83M.
  • Acuta Capital Partners first reported a position in Coherus Oncology in Q2 2018 and held it in 2 quarters.
  • Acuta Capital Partners's Coherus Oncology position peaked at $5.83M in Q3 2018.
  • 111 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2018.

Based on Acuta Capital Partners's 13F filing for Q4 2018, filed 14 Feb 2019.